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ABSTRACT 
Chemotherapy-induced nausea and vomiting (CINV) significantly reduce the life quality of 
cancer patients. A 5-HT3 receptor antagonist, corticosteroid, and H2-blocker have been used to control 
moderate nausea and vomit in cancer patients. The exploration of the cost-effectiveness of several 
antiemetic combinations in breast cancer patients in Prof. Dr. Margono Soekardjo Hospital, 
Purwokerto, Indonesia was the aim of this research. Seventy-four Breast cancer patients who have 
prescribed moderate-emetogenic chemotherapy during the year 2017-1019 were included in this 
research. There were fifteen patients treated with the combination of ondansetron and dexamethasone 
(OD). Fourteen patients were treated with the combination of ondansetron and ranitidine (OR). Thirty-
five patients were treated using ondansetron, dexamethasone, and ranitidine (ODR) combination. The 
effectiveness was represented by the absence of acute nausea and vomiting after receiving 
chemotherapy. The ODR combinations showed the highest effectivity on diminishing nausea and 
vomiting among breast cancer patients (0.400), followed by the OD combination (0.267) and the OR 
combination (0.214). However, the ODR combination generates the highest cost (4.6 million rupiahs) 
compared to other antiemetics combinations. Compared to the combination of ondansetron and 
dexamethasone, the combination of ODR provides higher ICER (ICER of 13 Million Rupiahs per case 
prevented) than the combination of OR (ICER of 8.5 million Rupiahs per case prevented). In 
conclusion, the combination of ondansetron, dexamethasone, and ranitidine generates the highest cost. 
It also provides the highest effectiveness in preventing nausea and vomiting. 
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Breast cancer is one of the leading health problems for women in the world. In 2018, breast 
cancer prevalence and incidence became the highest case among Indonesian women. It stated that 
there were about 58.256 new cases of breast cancer diagnosed in women (Ferlay et al., 2018; Jemal et 
al., 2011). Chemotherapy is one of the effective treatments in breast cancer management. It potentially 
decreases tumor size by about 50%, a 70% of patients who received chemotherapy experienced a 
decrease in cancer stage (Diaby et al., 2015). 
Although chemotherapy provides substantial-effectiveness among cancer patients, the side 
effects, particularly nausea and vomiting, of chemotherapy also affect patient adherence and quality of 
life (Diener, 1998; Engstrom et al., 1999; Hesketh, 2008). Chemotherapy-induced nausea and 
vomiting (CINV) are one of the most common side effects experienced by cancer patients who 
received chemotherapy. There were 70-80% of cancer patients who experience nausea and vomiting 
due to chemotherapy will delay or refuse further cycles of chemotherapy. It reduces the patient's 
compliance and quality of life (Greimel et al., 2009). Therefore, the addition of antiemetics for patients 
who received chemotherapy is an essential part of breast cancer therapy, particularly in preventing 
nausea and vomiting and improve the patient's quality of life (Hesketh, 2008). Since CINV potentially 
extends the length of treatment, the treatment cost for cancer patients is sometimes substantially 
increased (Schädlich et al., 2013). 
Several medicines have been used in practice and showed various effects on preventing nausea 
and vomiting (Navari and Aapro, 2016; Shankar et al., 2015). The sole use of 5-HT3 receptor 
antagonists prevents vomiting incidents for about 50% to 70% among cancer patients (Navari, 2015). 
Corticosteroids are recommended in combination with 5-HT3 antagonists for patients who received 
moderate emetogenic chemotherapy agents (Perez, 1998). In addition, intravenous dexamethasone has 
been used to prevent nausea and vomiting caused by chemotherapy (Diener, 1998). Since it has a long 
half-life in the body, it can also provide long protection for nausea and vomiting. 
The use of antiemetics in both and the combination could generate various effectiveness and 
cost in preventing nausea and vomiting. Therefore, cost-effectiveness analysis is required to explore 
the cost ratio and its effectivity on many antiemetic combinations. 
  
METHOD 
This cost-effectiveness analysis was done by collecting observational cohort data, in both 
clinical and economic analysis. The participants were the breast cancer patients who were treated at 
Prof. Dr. Margono Soekardjo Hospital, Purwokerto, Indonesia. The data was taken from the year 2017 
to 2019. The patients were females who were older than 18 years old. They received initial moderate-
emetogenic chemotherapy and antiemetics 30 minutes before receiving chemotherapy. The exclusion 
criteria were pregnant patients who experienced morning sickness, patients who refused to participate 
in this study. According to various guidelines (Hesketh, 2008), combination chemotherapy series were 
considered moderate emetogenic chemotherapy. It includes Doxorubicin 50 mg/m2 i.v. and 
Cyclophosphamide 600 mg/m2 (AC regiment). Doxorubicin 60 mg/m2 i.v.. Paclitaxel 175 mg/m2 i.v.. 
Cyclophosphamide 600 mg/m2 (ATC regiment). Cyclophosphamide 500 mg/m2 i.v.. Doxorubicin 50 
mg/m2 i.v.. and Fluorouracil 500 mg/m2 i.v. (CAF regiment). Cyclophosphamide 600 mg/m2 i.v.. 
Methotrexate 40 mg/m2 i.v. and Fluorouracil 600 mg/m2 i.v. (CMF regiment). and Cyclophosphamide 
75 mg/m2 i.v. Epirubicin 100 mg/m2 i.v. Fluorouracil 500 mg/m2 i.v. (CEF/FEC regiment). This 
study has been approved by the ethical committee (KEPK/UMP/22/I/2020).  
Patients were classified according to the antiemetics that they received during chemotherapy: 
ondansetron and dexamethasone (OD) group, ondansetron and ranitidine (OR) group, ondansetron, 
dexamethasone, and ranitidine (ODR) combination. The information on the type of antiemetics and 
chemotherapy was collected from medical records. The comparator of this study is the OD group. The 
researcher took the recommendations from several guidelines such as the Multinational Association of 
Supportive Care in Cancer (MASCC), The American Society of Clinical Oncology (ASCO), The 
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National Comprehensive Cancer Network (NCCN), and the European Society for Medical 
Oncology (ESMO) (Hesketh, 2008). 
In this study, a societal perspective is implemented (Assessment, 2017). In addition, the 
calculation includes all expenses associated with the patient’s treatment and illness. The data 
considered the direct medical cost, direct non-medical cost, and indirect cost. The direct medical cost 
consists of administration, laboratory, treatment costs (professional fee and radiotherapy), and 
medicine (chemotherapy and non-chemotherapy). The hospital billing became the main bill to collect 
the costs. The direct non-medical costs cover all expenses during treatment periods include 
transportation, parking, accommodation, and food. Finally, it was indirect costs. Consideration of 
productivity loss due to the illness and the treatment became the calculation of indirect cost. The 
productivity loss was calculated based on the patients' daily income and multiplied by the number of 
the hospitalization. It also included the possibility of the absence from work due to their illness. Both 
direct non-medical cost and indirect cost were collected by interviewing directly to the patients.  
The absence of nausea or vomiting on the patients as the result of chemotherapy up to 24 hours after 
chemotherapy was considered the effectivity of antiemetics. These clinical outcomes were presented 
as nausea only, vomiting only, and patients who experienced both side effects. The researcher uses the 
medical record to collect all of the clinical data. 
This research used A Chi-Square test to evaluate the differences in patients' characteristics 
include age, residence, educational background, occupation, types of health insurance, cancer stages, 
body mass index (BMI), and chemotherapy regimens. The differences in clinical outcomes were also 
analyzed using Chi-Square. The differences in cost among groups were analyzed using the Kruskal 
Wallis test. Finally, the research reached the main result of the cost-effectiveness analysis. The 
Incremental Cost-Effectiveness Ratio (ICER), as stated in (Setiawan et al., 2016) was calculated by 
dividing the incremental cost and the incremental effectiveness.  
 
RESULT AND DISCUSSION 
Initially, 556 patients were identified according to their diagnosis (C50.9). The confirmation process 






















Patients were excluded due to several reasons: 
 179 patients live outside of  the study area (Banyumas, 
Purbalingga, Cilacap, and Banjarnegara Districts) 
 121 patients used radiation therapy only 
 180 patients have ever received chemotherapy 
 2 of the patients were pregnant 
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Table 1. Breast cancer patient characteristics 
Patient characteristics OD (n=15) OR (n=14) ODR (n=45) Total (n=74) P-value 
Age (%) 
20-29 years old 
30-39 years old 
40-49 years old 
50-59 years old 





















































































Junior high school 

































































































































































OD: ondansetron and dexamethasone; OR: ondansetron and ranitidine; ODR: ondansetron. dexamethasone and ranitidine; 
BPJS PBI: Badan Pengelola Jaminan Sosial Penerima Bantuan Iuran; BPJS non PBI: Badan Pengelola Jaminan Sosial non 
Penerima Bantuan Iuran; Jamkesda: Jaminan Kesehatan Daerah; YPP: Yayasan Kesehatan Pertamina; FAC: Fluorouracil 500 
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mg/m2 i.v.. Doxorubicin 50 mg/m2 i.v.. and Cyclophosphamide 500 mg/m2 i.v.; AC: Doxorubicin 50 mg/m2 i.v. and 
Cyclophosphamide 600 mg/m2; ETC: Epirubicine 100 mg/m2 i.v.. Paclitaxel 175 mg/m2 i.v.. Cyclophosphamide 75 mg/m2 
i.v.; ET: Epirubicine 100 mg/m2 i.v.. Paclitaxel 175 mg/m2 i.v. 
 
Seventy-four breast cancer patients were included in the final analysis. Most of the age patients 
were in the range of 40 to 60 years old. They also have an average Body Mass Index (BMI of 18.5 to 
24.9). The socioeconomic factor of the patients showed that most of them lived in the Banyumas 
district (54.0%), finished elementary school (51.4%), were a housewife (51.4%) and used BPJS non-
PBI scheme for their health insurance. 
The clinical background of the patients (Table 1) showed that most of them were in the breast 
cancer stage III (48.6%). They received the combination of Epirubicin 100 mg/m2 i.v. and Paclitaxel 
175 mg/m2 i.v. regiments (47.3%). Overall, there are no significant differences in both socioeconomic 
and clinical characteristics among anti-emetics groups (all p values are higher than 0.05). 
 
Table 2. Comparison of the effectiveness of the antiemetic regimen by looking at the incidence of nausea 
and vomiting 
Side Effects OD (n=15) OR (n=14) ODR (n=45) p-value 
Nausea (%) 8 (53.3) 11 (78.6) 23 (46.7) 0.112 
Vomiting (%) 5 (33.3) 8 (57.1) 11 (24.4) 0.074 
Nausea and Vomiting (%) 11 (73.3) 11 (78.6) 27 (60.0) 0.355 
No nausea and no vomiting (%) 4 (26.7) 3 (21.4) 18 (40.0) 0.355 
OD: ondansetron and dexamethasone; OR: ondansetron and ranitidine; ODR: ondansetron, 
dexamethasone and ranitidine 
 
The incidence of nausea and or vomiting solely among patients who received OD and OR 
combination is noticeably higher than the patient who was treated using ODR combination. Breast 
cancer patients in the OR group experienced the highest nausea (78.6%), vomiting (57.1%), and the 
combination of both nausea and vomiting (78.6%). However, the differences in the side effects 
experienced are not statistically significant (all p values are higher than 0.05) (Table 2). 
 
Table 3. The cost of illness (in 1.000 rupiahs) of breast cancer patients in Prof. Dr. Margono Hospital 
Type of cost 
(x 1.000 rupiahs) 
OD OR ODR 
Mean SD Mean SD Mean SD 




















































































Total 2.825.9 816.9 2.374.5 504.5 4.557.9 1,792.8 
OD: ondansetron and dexamethasone; OR: ondansetron and ranitidine; ODR: ondansetron, 
dexamethasone and ranitidine 
 
During their hospitalization, breast cancer patients who were included in OD (Rp.1.6 Million) 
and OR (Rp.1.9 Million) groups mostly spent their resources on treatment such as fees for doctors and 
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nurses or radiotherapy, while the patient in the ODR group mostly spent their resources for the 
medication (Rp.2.6 Million) (Table 3). Concerning the direct cost that had been spent for non-medical 
items, patients in OD (Rp.53 Thousand) and OR (Rp.54 Thousand) groups spent most of the resources 
for the transportation to the hospital. In contrast, patients in the ODR group spent most of the 
resources for accommodation (RP.230.1 thousand). In this study, patients in OR groups experienced 
the greatest loss in their productivity (Rp.149 Thousand) due to their illness and or treatments. 
 
Table 4. Cost-effectiveness analysis of antiemetic therapy in breast cancer patients 




Ondansetron, dexamethasone 2,825,883 0.267 - - - 
Ondansetron, ranitidine 2,374,440 0.214 -451,443 -0.053    8,517,792 
Ondansetron, 
Dexamethasone, ranitidine 
4,560,550 0.400 1,734,667 0.133  13,042,609 
ICER: Incremental Cost-Effectiveness Ratio 
 
Compared to the antiemetic OD combination, the cost of treatment of OR combination was 
lower (-Rp.451 Thousand). However, it prevented less nausea and vomiting (-0.053) in breast cancer 
patients (Table 4). On the other hand, the ODR combination increases the prevention of nausea and 
vomiting (0.133) among breast cancer patients, but the consequence is that the cost of treatment was 
also increased (Rp.1.7 Million). Although both alternatives, OR and ODR combination, generate 
positive ICER, the location of both alternatives is different. The OR combination is located at the third 
quadrant of the Cost-Effectiveness Plane (CEP). The ODR combination is located at the first quadrant 
with the ICER of Rp13 Million for each nausea and vomiting case prevented.  
 
Discussion 
In terms of clinical outcome in Indonesia, this study is the first economic evaluation providing 
evidence that compared the recommended standard of care for chemotherapy-induced nausea and 
vomiting. The combination of ondansetron, dexamethasone, and ranitidine (ODR) provides higher 
prevention of nausea and vomiting-induced chemotherapy and increases the cost of treatments for 
breast cancer patients in Indonesia. However, this combination is clinically acceptable since it is also 
recommended by some guidelines, such as the National Comprehensive Cancer Network (NCCN).  
The addition of ranitidine in the existing regiment will increase the total cost of treatment. This finding 
is similar to several other studies, although the types of chemotherapy used are different (Pradermdee 
et al., 2006). The increase in the ODR combination cost was not significantly different. However, this 
increase must be carefully considered since the treatment cost for any diseases in Indonesia is limited 
by the standard price, namely Indonesian Case-Based Group (INA-CBGs) (Indonesia, 2013). 
 From the clinical perspective, the ODR combination should be preferred as the main 
recommendation for patients who will potentially gain the highest benefit such as the age of 40 to 60 
years old, having normal BMI (18.5-24.9), in stage III of breast cancer, and receiving ET 
chemotherapy combination. The consideration is essential since chemotherapy-induced nausea and 
vomiting is one of the main issues that increase chemotherapy failure. Patients generally refuse to 
continue the therapy plan if this side effect is substantially reducing their life quality. The mechanism 
of this side effect is that chemotherapy drugs generally increase the secretion of substance P from 
neurons in the nervous systems and then binds to neurokinin-1 (NK1) receptors to induce vomiting 
(Muñoz and Coveñas, 2019). Based on chemotherapy-induced nausea and vomiting, there is a 
considerably new antiemetic therapy, Aprepitant - a selective neurokinin-1 receptor antagonist, that 
has been used widely to prevent chemotherapy-induced nausea and vomiting. It showed that the 
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combination uses Aprepitant was also cost-effective for this purpose (Kang et al., 2018). However, this 
new drug has not been registered for the Indonesian market.  
One of the advantages of this study is that this study used the clinical outcome of chemotherapy-
induced nausea and vomiting. Nausea and vomiting are important issues since it has been known as 
the main obstacles of the successfulness of chemotherapy. This study will be beneficial for 
communication with the clinician since their main concern is mostly clinical benefit for patients. 
However, since health economic evaluation is generally used to encourage the decision-maker, who 
are usually not only consider clinical outcome but also economic outcome, this study provides less 
comprehensive recommendation since the ICER could not be compared with any willingness to pay 
which uses utility or  Quality Adjusted Life Years (QALYs) as the denominator in the formula.  
We understand that this study has limited samples. The sample was only from one hospital in 
Indonesia. This limitation could potentially reduce the applicability of the results. However, most of 
the hospitals in Indonesia that take care of cancer patients are of the same type as Prof Dr. Margono 
Public Hospital, which is a type B accredited hospital. There is a very limited type C hospital that has 
the capacity and capability on treating cancer patients in Indonesia and therefore, this study's results 
can be, at least, implemented in many other type B hospitals in Indonesia. In addition, several factors 
could influence the value of treatment cost such as the class of hospitalization, types of chemotherapy 
used, and also patient comorbidities. Therefore, more data is required to perform the subgroup analysis 
to evaluate the impact of those confounding factors on the treatment cost.  
Another limitation of this study is that nausea and vomiting were collected from medical 
records. Chemotherapy-induced nausea and vomiting information should be confirmed using various 
checklists such as the Naranjo checklist or WHO-UMC criteria (Belhekar et al., 2014;García-Cortés et 
al., 2008). This confirmation process can theoretically increase the validity of the relation between 
chemotherapy and the side effect of nausea and vomiting experienced by the patients. Therefore, 
further research is required to improve our findings on the cost-effectiveness analysis of antiemetic 
therapy to prevent chemotherapy-induced nausea and vomiting in cancer patients by including more 
patients and more hospitals. The next study also has to consider QALYs as the outcome of the therapy.  
 
CONCLUSION 
In conclusion, our study showed that although both combinations (OR and ODR) are 
considerably cost-effective strategies for reducing nausea-related chemotherapy on breast cancer 
patients, the combination of ondansetron, dexamethasone, and ranitidine is considered the most 
favorable option since it offers more benefits and an acceptable additional cost.  
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